A multi-organ approach
Team leader: Pr Alexandre Loupy MD, PhD
Driven by a desire to be innovative, we are interested in cutting-edge techniques such as deep phenotypic analysis. Our mission is to tackle the complexities of organ transplantation, in order to revolutionize organ allocation for the benefit of transplant patients. By bringing together experts from diverse fields, we foster collaboration, making inclusion and well-being an integral part of our culture. We believe in creating innovations that transform lives, and our commitment to teamwork is the driving force behind our pursuit of revolutionary solutions in the field of transplantation.
Integrative research
We have developed a innovative scientific approach closely combining clinical investigations and statistics. The probabilistic mathematical tool is used in an integrative thinking approach, coupled at many levels with questions, insights and clinical investigations.
We called this approach « integrative epidemiology ».
This approach received the ATC Award 2017, the "Grand Prix de l'Académie de Médecine 2018" by the French Academy of Medicine in Paris (France) and the "Prix de l'Inserm 2023".
Data Driven Science
So far, many results derived from large registries (UNOS in the US, Eurotransplant, National French Agency for Organ Procurement). They have a high value for descriptive purposes (prevalence and incidence), they do not provide per se insights in pathogenesis, risk prediction and personalised transplant medicine.
Our approach uses exceptionally large prospective unselected cohorts with a very high level of detail (deep phenotyping), to test cutting-edge technologies with powerful and robust methodological tools.
The large quantity of information gathered from thousands of patients at multiple points in time allows us to take advantage of big data / smart data approach.
Ibox : Prediction system for renal allograft loss
This is the first international study of risk prediction in kidney transplant recipients
Developed and validated across several large independent populations and in randomised controlled clinical trials. The iBox score represents a novel integration of demographic, functional, histological, and immunological factors that can be implemented in routine clinical practice. It has potential to upgrade the shared decision making process for transplant patients and represents a valid and early surrogate endpoint for clinical trials and drug development in transplantation.
From Allo- to Xenotransplantation
The team has recently embarked on a new research avenue aiming to transfer our precision diagnostic approach from allo- to xenotransplantation in order to decipher the immunological process involved in the xenoimmune response. Multimodal phenotyping of xenografts is a necessary step to bring xenotransplantation from experimental investigation to clinical trials in living human recipients. For this purpose, our team establishes scientific collaborations with leading teams in xenotransplantation, to adapt our precision medicine approach from allo to xenotransplantation.
